Project I Test: Implementing HIV Testing in Opioid Treatment Programs
Launched by COLUMBIA UNIVERSITY · Apr 26, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called Project I Test, is focused on improving the way opioid treatment programs (OTPs) offer HIV and Hepatitis C testing to their patients. The study will test two different methods of support, known as "practice coaching," to see which one helps more patients get tested for HIV and linked to medical care. The goal is to find out how effective these methods are in encouraging patients to receive these important tests and follow-up care, especially for those struggling with substance use disorders.
To be eligible for this trial, treatment centers must serve at least 150 unique patients each year and be willing to collect data on testing and referrals. Participants in the trial can expect to be part of a program that aims to enhance their access to HIV and Hepatitis C testing, ensuring they receive timely support if needed. This study is currently recruiting participants and is open to all genders between the ages of 65 and 74. The results from this trial could lead to better healthcare practices and improved health outcomes for individuals in opioid treatment programs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Eligible sites must:
- • 1. See at least 150 unduplicated patients/year/site
- • 2. Be capable and willing to prospectively collect data on the number of patients who a) are offered any HIV and/or HCV tests; b) completed these tests; c) are referred to care/evaluation (and type of referral) if positive; and d) are linked to care/evaluation within 30 days of diagnosis
- • 3. Be capable and willing to provide patient demographics, testing data within demographic categories of gender and race/ethnicity (in aggregate) and data on HIV/HCV test reimbursement processes and outcomes
- • 4. Have key staff willing to consent to participate in study surveys, qualitative interviews and intervention coaching throughout the study
- Exclusion Criteria:
- * Sites will be excluded if:
- • 1. Over 50% of patients served in the prior 6 months were HIV or HCV tested
- • 2. They are terminated via PI decision/discretion
About Columbia University
Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Lisa Metsch, PhD
Principal Investigator
Columbia University
Daniel Feaster, PhD
Principal Investigator
University of Miami
Jemima Frimpong, PhD
Principal Investigator
New York University Abu Dhabi
Lauren Gooden, PhD
Study Director
Columbia University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials